Patients with NSCLC may continue to benefit from adjuvant chemotherapy even when it is administered beyond the traditional postoperative window.
Why this matters
In appropriate patients, physicians should consider chemotherapy up to 4 mo after surgery if patients are able to tolerate it.
Retrospective observational study that evaluated 12, 473 treatment-naive patients with NSCLC identified from the National Cancer Database with completely resected tumors and who received adjuvant multiagent chemotherapy between 18 and 127 d after surgery.
Funding: Not disclosed.
3 groups were identified: earlier subgroup (18-38 d in chemotherapy initiation), reference interval (39-56 d), and later subgroup (57-127 d).
There was no consistent correlation between mortality risk and timing of adjuvant chemotherapy:...